We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

135 hedge funds and large institutions have $1.1B invested in Viridian Therapeutics in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 54 increasing their positions, 37 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

246% more call options, than puts

Call options by funds: $7.59M | Put options by funds: $2.19M

87% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 15

46% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 37

11% more funds holding

Funds holding: 122 → 135 (+13)

2.05% less ownership

Funds ownership: 102.45% → 100.39% (-2.1%)

9% less capital invested

Capital invested by funds: $1.21B → $1.1B (-$110M)

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
135
Holders Change
+13
Holders Change %
+10.66%
% of All Funds
2.15%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.11%
New
28
Increased
54
Reduced
37
Closed
15
Calls
$7.59M
Puts
$2.19M
Net Calls
+$5.4M
Net Calls Change
+$5.51M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$36.2M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$33.4M
3
HRCM
Hood River Capital Management
Florida
+$18.2M
4
PCH
Polar Capital Holdings
United Kingdom
+$17.6M
5
State Street
State Street
Massachusetts
+$17.3M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$35.9M
2
BI
BVF Inc
California
-$34.3M
3
DTC
Deep Track Capital
Connecticut
-$17.3M
4
KCM
Kynam Capital Management
New Jersey
-$15.7M
5
TCM
TCG Crossover Management
California
-$10.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$70.6M +$379K +11,830 +0.4%
VA
2
VR Adviser
New York
$68.7M – – –
State Street
3
State Street
Massachusetts
$61.1M +$17.3M +538,622 +29%
CC
4
Commodore Capital
New York
$55.7M +$5.43M +169,493 +8%
Vanguard Group
5
Vanguard Group
Pennsylvania
$54.2M +$489K +15,239 +0.7%
PBA
6
Paradigm Biocapital Advisors
New York
$53.1M +$10.7M +334,531 +19%
RCM
7
RA Capital Management
Massachusetts
$51.1M +$36.2M +1,127,946 +128%
PA
8
Perceptive Advisors
New York
$44.2M +$16.5M +515,811 +42%
VC
9
Vivo Capital
California
$42.7M – – –
FFM
10
Fairmount Funds Management
Pennsylvania
$34.8M – – –
AllianceBernstein
11
AllianceBernstein
Tennessee
$31.7M +$10.3M +320,317 +35%
DTC
12
Deep Track Capital
Connecticut
$31.3M -$17.3M -540,895 -31%
YCM
13
Yiheng Capital Management
California
$31.3M +$8.51M +265,278 +28%
OCA
14
Octagon Capital Advisors
New York
$30.1M +$11.6M +360,800 +44%
PAMS
15
Pictet Asset Management (Switzerland)
Switzerland
$26.5M +$33.4M +1,042,965 New
LGM
16
Logos Global Management
California
$24.2M -$1.6M -50,000 -5%
CAM
17
Cormorant Asset Management
Massachusetts
$21.6M -$8.02M -250,000 -23%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$19.7M +$2.09M +65,127 +9%
TCM
19
Tang Capital Management
California
$17.6M – – –
TCM
20
TCG Crossover Management
California
$16.9M -$10.3M -320,000 -33%
Marshall Wace
21
Marshall Wace
United Kingdom
$16M +$573K +17,863 +3%
Millennium Management
22
Millennium Management
New York
$15.6M -$5.51M -171,765 -22%
N
23
Nuveen
North Carolina
$14.7M +$8.21M +256,161 +80%
HRCM
24
Hood River Capital Management
Florida
$14.4M +$18.2M +566,498 New
PCH
25
Polar Capital Holdings
United Kingdom
$14M +$17.6M +550,000 New
1
2 3 4 5

VRDN Hedge Fund Activity: Q1 2023 in Review

135 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2023, worth a combined $1.1B — down 9.1% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VRDN positions and 15 closed out — a net gain of 13 holders — while 54 added to existing stakes and 37 trimmed.

The largest buyer was RA Capital Management, adding an estimated $36.2M. The largest seller was Citadel Advisors, cutting an estimated $35.9M.

  • 135 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2023, up from 122 in Q4 2022.
  • Funds reported $1.1B of Viridian Therapeutics stock for Q1 2023, down 9.1% quarter-over-quarter.
  • 28 funds opened new Viridian Therapeutics positions in Q1 2023 and 15 closed out, a net change of +13 holders.
  • The largest Viridian Therapeutics buyer in Q1 2023 was RA Capital Management, an estimated $36.2M added.
  • The largest Viridian Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $35.9M sold.

Based on aggregated 13F filings for Q1 2023.